Skip to main content
SpringerLink
Log in

Mineralstoffpräparate und Osteoporosemittel

  • Chapter
Book cover Arzneiverordnungs-Report 2006

  • 422 Accesses

Auszug

Hauptvertreter der Mineralstoffpräparate sind Calcium-, Kalium- und Magnesiumpräparate. Kaliumpräparate dienen der Korrektur eines höhergradigen Kaliummangels. Magnesiumpräparate sind bei Magnesiummangelzuständen indiziert, die aber bei der weiten Verbreitung von Magnesium in der Nahrung bei üblicher Kost selten sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Medical Association (1986): Agents affecting calcium metabolism. In: Drug Evaluations, 6th ed, Saunders Company, Philadelphia, pp. 827–839, 885–902.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2003): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 1. Auflage. Im Internet: www. akdae.de/35/83_Osteoporose_2003_1Auflage.pdf

    Google Scholar 

  • Bone HG, Hosking D, Devogelaer D et al (2004): Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.

    Article  PubMed  CAS  Google Scholar 

  • Crowther CA, Hiller JE, Doyle LW, Haslam RR (2003): Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA 290: 2669–2676.

    Article  PubMed  CAS  Google Scholar 

  • Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997): Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670–676.

    Article  PubMed  CAS  Google Scholar 

  • Djavan B, Thompson I, Michel MS, Waldert M, Seitz C (2004): Chemoprävention des Prostatakarzinoms. Urologe A 43: 557–561.

    Article  PubMed  CAS  Google Scholar 

  • Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group (2003): Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95: 1477–1481.

    PubMed  CAS  Google Scholar 

  • Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999): Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645.

    Article  PubMed  CAS  Google Scholar 

  • Fassbender WJ, Stumpf UC, Jockenhövel F (2006): Evidenzbasierte medikamentöse Therapie der Osteoporose. Med Klinik 101Sondernr. 1: 178–181.

    Google Scholar 

  • Fleisch H (2000): Bisphosphonates in bone disease. From the laboratory to the patient. 4th ed, Academic Press, San Diego etc., pp. 1–212.

    Google Scholar 

  • Galloe AM, Rasmussen HS, Jorgensen LN, Aurup P, Balslov S et al (1993): Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. Brit Med J 307: 585–587.

    Article  PubMed  CAS  Google Scholar 

  • Guerrero-Romero F, Tamez-Perez HE, González-González E et al (2004): Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 30: 253–258.

    Article  PubMed  CAS  Google Scholar 

  • Haguenauer D, Welch V, Shea B, Tugwell P, Wells G (2000): Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2000;(4):CD002825.

    Google Scholar 

  • Hersh AL, Stefanick ML, Stafford RS (2004): National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 291: 47–53.

    Article  PubMed  CAS  Google Scholar 

  • ISIS-4 Collaborative Group (1995): ISIS-4: a randomised Arctoriol trial assessing early oral Captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345: 669–685.

    Article  Google Scholar 

  • Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.; Women’s Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669–683.

    Article  PubMed  CAS  Google Scholar 

  • Kuhlmann U, Siegenthaler W, Siegenthaler G (1987): Wasser-und Elektrolythaushalt. In: Siegenthaler W. (Hrsg): Klinische Pathophysiologie. Georg Thieme Verlag, Stuttgart New York, S. 209–237.

    Google Scholar 

  • Lacour M, Zunder T, Restle A, Schwarzer G (2004): No evidence for an impact of selenium supplementation on environment associated health disorders — a systematic review. Int J Hyg Environ Health 207: 1–13.

    Article  PubMed  CAS  Google Scholar 

  • Manz M, Mletzko R, Jung W, Lüderitz B (1990): Behandlung von Herzrhythmusstörungen mit Magnesium. Dtsch Med Wschr 115: 386–390.

    Article  PubMed  CAS  Google Scholar 

  • Meunier PJ, Roux C, Seeman E et al (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–486.

    Article  PubMed  CAS  Google Scholar 

  • Meyer P, Boettger MB (2001): Familial hypomagnesaemia with second hypocalcemia: A new case that indicates autosomal recessive inheritance. J Inherit Metab Dis 24: 875–876.

    Article  PubMed  CAS  Google Scholar 

  • Miller PD, Watts NB, Licata AA et al (1997): Cyclical etidronate in treatment of postmenopausal osteoporosis. Am J Med 103: 468–476.

    Article  PubMed  CAS  Google Scholar 

  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001): Effect of parathyroid hormone (1—34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.

    Article  PubMed  CAS  Google Scholar 

  • NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942–1948.

    Article  Google Scholar 

  • Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005): Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90: 2816–2822.

    Article  PubMed  CAS  Google Scholar 

  • Riggs BL, O’Fallon WM, Lane A, Hodgson SF, Wahner HW et al (1994): Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 9: 265–275.

    Article  PubMed  CAS  Google Scholar 

  • Roffe C, Sills S, Crome P, Jones P (2002): Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Med Sci Monit 8: CR326–330.

    PubMed  CAS  Google Scholar 

  • Shiga T, Wajima Z, Inoue T, Ogawa R (2004): Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Med 117: 325–333.

    Article  PubMed  CAS  Google Scholar 

  • Wüster C, Ziegler R (1993): Fluorid-Therapie der Osteoporose: „Auf die Dosis kommt es an“. Dtsch Ärztebl 90: B-41–42.

    Google Scholar 

  • Zehender M, Meinertz T, Faber T, Caspary A, Jeron A et al (1997): Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. J Am Coll Cardiol 29: 1028–1034.

    Article  PubMed  CAS  Google Scholar 

  • Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570–577.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

  2. Mozartstraße 20, 69121, Heidelberg

    Prof. Dr. med.h.c. Reinhard Ziegler

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med.h.c. Reinhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U., Ziegler, R. (2007). Mineralstoffpräparate und Osteoporosemittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation